Table 1. Patient demographics and baseline characteristics (safety population).
| Characteristic | Dose-escalation cohort (N = 19) | Dose-expansion cohort (N = 19) | Total population (N = 38) |
|---|---|---|---|
| Age, median (range), years | 60 (28–78) | 65 (37–77) | 64 (28–78) |
| Sex, n (%) | |||
| Male | 13 (68.4) | 10 (52.6) | 23 (60.5) |
| Female | 6 (31.6) | 9 (47.4) | 15 (39.5) |
| ECOG PS, n (%) | |||
| 0 | 7 (36.8) | 9 (47.4) | 16 (42.1) |
| 1 | 11 (58.9) | 8 (42.1) | 19 (50.0) |
| 2 | 1 (5.3) | 2 (10.5) | 3 (7.9) |
| Primary cancer site, n (%) | |||
| Stomach (gastric cancer) | 8 (42.1)* | 14 (73.7) | 22 (57.9) |
| Colorectal | 5 (26.3) | 1 (5.3) | 6 (15.8) |
| Lung | 2 (10.5)* | 2 (10.5) | 4 (10.5) |
| Pancreas | 1 (5.3) | 0 (0) | 1 (2.6) |
| Breast | 1 (5.3) | 0 (0) | 1 (2.6) |
| Unknown primary | 0 (0) | 1 (5.3) | 2 (5.3) |
| Kidney | 0 (0) | 1 (5.3) | 1 (2.6) |
| Thymus | 1 (5.3) | 0 (0) | 1 (2.6) |
| Number of previous anticancer therapies, n (%) | |||
| 1 | 0 (0) | 5 (26.3) | 5 (13.2) |
| 2 | 4 (21.1) | 3 (15.8) | 7 (18.4) |
| ≥ 3 | 15 (78.9) | 11 (58.9) | 26 (68.4) |
*Two patients with gastric cancer and one patient with lung cancer from the dose-escalation cohort had MET-amplified tumors. In the dose-expansion cohort, all patients had MET-amplified tumors.
ECOG, Eastern Cooperative Oncology Group; PS: performance status.